Exploring Artificial Intelligence in Drug Discovery

Artificial intelligence is rapidly reshaping the drug discovery process, moving from augmenting research to actively driving innovation. As biotech companies face soaring R&D costs and long development cycles, AI promises a breakthrough: slashing drug development time by nearly half while improving accuracy in identifying promising compounds. With global pharmaceutical R&D spending projected to exceed $230 billion by 2026, efficiency isn’t just desirable—it’s critical.

Can AI transition drug discovery from a serendipitous search to a precise, design-led process? And what are the real-world applications—and limitations—of machine learning in today’s labs?

In this episode of Crowncast by Crown BioScience, host Jonny McMichael welcomes Kuan Yan, Senior Principal Scientist, and Jordan Lim, Associate Director of Digital Product. Together, they explore how AI is being used to automate workflows, optimize molecular designs, and provide advisory-level insights within CRO environments—all while navigating the complexities of regulation and data privacy.

Key Highlights:

  • AI is already accelerating early-stage drug discovery, from target identification to molecule generation and optimization—cutting development timelines dramatically.

  • Human-in-the-loop remains essential, especially for quality control, validation, and navigating the risks of AI’s “black box” nature.

  • Crown BioScience is developing internal AI frameworks to transform data into insights, optimize experimental designs, and ultimately deliver more value to clients.

Jordan Lim holds a bachelor’s and MBA from the University of California, San Diego, and brings a unique perspective from his work in patient advocacy, study coordination, and digital transformation at Crown BioScience.

Kuan Yan earned his master’s and PhD in bioimaging and image analysis from the University of Leiden. With over 15 years of experience in machine learning, he now leads AI initiatives as a Senior Principal Scientist at Crown BioScience Netherlands.

Recent Episodes

Dr. Danielle Dang, Senior Medical Director at Maven Clinic, joins Brent to explore how Maven delivers holistic, virtual-first care across every stage of the family journey—from fertility to menopause. Drawing from her own 7-year infertility experience, Dr. Dang shares how Maven’s model reduces IVF reliance, improves birth outcomes through doula support, and closes care gaps…

Dr. Kristin Gill, Behavioral Health Medical Director at Anthem, joins Brent to explore the realities of maternal mental health—both as a clinical leader and new mother herself. Drawing from her experience in perinatal psychiatry and acute behavioral care, Dr. Gill unpacks the critical link between maternal well-being and child health, the post-COVID surge in demand…

Hospitals are facing a deepening staffing crisis that threatens care delivery. More than 540,000 healthcare workers exited the field between February 2020 and September 2021, and hospital employment declined by nearly 94,000 during the same period. Projections indicate that over 6.5 million healthcare professionals could leave the workforce by 2026, creating a net shortfall…